Our Team

The BioIncept Management Team

Dr. Jacqueline H. Barnea, President, CEO, Chair, and Co-Founder of BioIncept, LLC

DR. JACQUELINE H. BARNEA

President, CEO, Chair, and Co-Founder of BioIncept, LLC

Dr. Jacqueline H. Barnea is the President, CEO and co-founder of BioIncept, LLC, a clinical stage biotechnology and intellectual property portfolio holding company that develops and manages the translation of the PreImplantation Factor (PIF) platform towards its intended clinical potential. Dr. Barnea brings her global vision, adaptability, flexibility and out-of-the-box thinking to this transformational technology project. She creates, adapts, and brings consensus to the scientific, legal and patent management of the PreImplantation Factor (PIF), the paradigm-shifting technology that is PIF.

Having earned her Doctorate summa cum laude in International Business Law in 1976 from the Sorbonne-Pantheon University in Paris, Dr. Barnea taught graduate-level students and corporate executive courses in decision-making, comparative management, international negotiations and marketing, while preparing for a corporate law and academic career. She redirected her career towards biotechnology upon co-founding BioIncept.

Dr. Barnea brings nearly two decades of uniquely adapted biotech building experience to BioIncept’s vast transformational platform. This journey began with global collaborations with leading scientists at prominent institutions, who then independently produced their own data and validated PIF scientific results. She has guided the PIF project from its inception to clinical reality, forging an innovative path for PIF by carefully monitoring pharmaceutical transition and adaptive reality. Dr. Barnea has surrounded herself with expert advisors and respected legal and patent teams to help her guide the Company successfully through uncharted territory.

Her next step at BioIncept is to safely shepherd PIF through FDA-approved, University-sponsored Phase I/II clinical trials, both therapeutic and diagnostic. At the completion of those trials, Dr. Barnea and her team will position BioIncept to leverage the appropriate industry partnerships to ensure that PIF reaches its full potential and that BioIncept provides therapeutic and diagnostic products to address a vast array of unmet global needs.

Dr. Eytan R. Barnea, Chief Scientific Officer, Director, and Co-Founder of BioIncept, LLC

DR. EYTAN R. BARNEA, MD, FACOG*

Chief Scientific Officer, Director, and Co-Founder of BioIncept, LLC

Dr. Eytan R. Barnea discovered the PreImplantation Factor (PIF) and is the Chief Scientific Officer and co-founder of BioIncept, LLC, a clinical stage company. His investigations of embryo-derived signaling in pregnancy translate his observations to clinical applications in fertility and immune regulation.

An embryo-secreted peptide, PIF is a powerful immune regulator and tolerance inducer that modulates the immune response, inflammation and transplant acceptance. As such, PIF holds the potential to ameliorate a vast array of diseases and conditions. Dr. Barnea leads a prestigious, interdisciplinary circle of collaborators from world-renowned universities and centers of excellence that lend their expertise and support into understanding PIF’s uniquely beneficial features and translate the science to its intended potential global reach.

Dr. Barnea is an internationally recognized authority on early pregnancy investigation. He has authored over 180 peer-reviewed scientific publications and book chapters and edited four specialty textbooks. In 1990 he founded the Society for the Investigation of Early Pregnancy (SIEP), an interdisciplinary, non-profit panel of scientists and clinicians, to explore this emerging medical field which holds such deep clinical implications. As SIEP Chairman, Dr. Barnea has convened five World Conference(s) on Early Pregnancy Investigation.

Among his awards and recognitions, Dr. Barnea received the Elkeles Prize ‘Scientist of the Year in Medicine’ in 1989 from the Israel Health Ministry/Jewish National Fund, and in 2012 he was awarded the Bratanov Medal and Prize of the International Society for Immunology of Reproduction (ISIR) for his contribution to the development of Immunology.

Dr. Barnea earned his medical degree cum laude from the University of Milan Medical School (1976). After starting his residency at the University of Pennsylvania and continuing at McGill University, he completed his training at Yale University, where he served as Chief Resident, Fellow, and Assistant Professor. Double board certified in OB-GYN and Reproductive Endocrinology, he is a dedicated clinician, including having served as Director of Obstetrics, Gynecology and Reproduction at CAMcare in New Jersey for many years. As a practicing physician, Dr. Barnea brings his unique clinical perspective to BioIncept.

* Fellow of The American Congress of Obstetricians and Gynecologists

The BioIncept Board of Directors

Julia D. Corelli, Director, BioIncept, LLC

JULIA D. CORELLI

Director, BioIncept, LLC

Ms. Corelli joined the BioIncept Board of Directors in October 2014. Having represented BioIncept at the law firm of Pepper Hamilton, LLP for more than 15 years, Ms. Corelli brings a deep knowledge of the company’s history and mission and a broad array of corporate governance and transactional experience. She has been a partner at Pepper for more than 20 years, with a practice focusing on counseling investment funds on formation, regulation and operations, as well as business and transactions counseling to family offices and life science companies. Ms. Corelli has served for 11 years on Pepper’s governing body and is currently its Vice Chair. She is also co-Chair of Pepper’s Commercial Department. Ms. Corelli has a BA from Yale in American History and a JD from Villanova University School Of Law and an LLM in taxation from Villanova’s Graduate Tax Program. Ms. Corelli serves on the BioIncept Board of Directors Compensation Committee.

David R. Duncan, Observer, BioIncept, LLC

DAVID R. DUNCAN

Observer, BioIncept, LLC

David R. Duncan became a Board Observer with the BioIncept Board in 2014. Mr. Duncan brings a strong background in financial management and strategic growth planning, and serves as a director for a number of banking and life sciences companies. Mr. Duncan is the President and CEO of Silver Oak Cellars and Managing Partner of Twomey Cellars, a family wine business founded by his father. Mr. Duncan also actively serves on the boards of First Western Trust Bank in Denver, Colorado; Just Right Surgical, also in Colorado; the Saint Helena Hospital Foundation Board; and currently serves as the Chairman of the Napa Valley Vintners Board. He is a member and Past Chairman of the Northern California Chapter of the Young Presidents Organization. Mr. Duncan graduated from University of Notre Dame in 1988, and earned his MBA, Finance from the University of Denver in 1994.

Brian K. Foster, Observer, Consultant, BioIncept, LLC

BRIAN K. FOSTER

Observer, Consultant, BioIncept, LLC

Brian K. Foster has been an advisor to BioIncept and a Board Observer since the summer of 2015. A 32-year veteran of JP Morgan, where he most recently served as Vice Chairman of JP Morgan’s Private Bank, Mr. Foster has advised many small and mid-sized companies on management consulting and financial growth strategies. Mr. Foster was recognized by Barrons in 2012 as the Top Private Banker and a top 100 investment advisor on several occasions. He has an MBA in Finance, Columbia University Business School, graduating with Beta Sigma Gamma honors and a BS in Information Systems Management from the University of Maryland. Mr. Foster is a member of Golden Seeds and an active private investor in life science and technology start-ups.

George W. Frank, Jr., Director, BioIncept, LLC

GEORGE W. (WOODY) FRANK, JR.

Director, BioIncept, LLC

George W. (Woody) Frank, Jr., was elected to the BioIncept Board of Directors in 2007, bringing a wide range of experience in finance, investment and equity markets. Mr. Frank worked for 21 years at Merrill Lynch & Co., and then joined Smith Barney and its succeeding firms, retiring from CitiGroup in 2001. At CitiGroup, Mr. Frank served as Head of the Equity Syndicate Department, Co-Head of Global Equity Capital Markets and Head of Global Equity Institutional Sales. He served for 10 years on the firm’s Investment Banking Commitment Committee. Mr. Frank participated in the review of all public, private and joint venture transactions for their acceptability prior to the firm’s participation. Mr. Frank graduated from the University of North Carolina in 1965 with a degree in Economics and Political Science. Mr. Frank serves on the BioIncept Board of Directors Compensation Committee.

Barton P. O’Brien, Director, BioIncept, LLC

BARTON P. O’BRIEN

Director, BioIncept, LLC

Barton O’Brien has been associated with BioIncept since February 2010 and joined the BioIncept Board of Directors in 2012. He has more than 30 years of experience in startup high-tech companies and brings to the Board a broad expertise in startup financing, company organization, and sales and marketing processes. After graduating from the University of Florida, BS/BA (honors), he then earned a Master of Science in Industrial Administration at Carnegie Mellon Graduate School of Industrial Administration. Mr. O’Brien was a co-founder of two successful software companies which reached more than $1.5 billion in market capitalization and has served as an executive for several other firms. Mr. O’Brien serves on the Carnegie Mellon Tepper Business School Alumni Board and is Chairman of the O’Brien Clan Foundation.

Dennis A. Spink, Director, BioIncept, LLC

DENNIS A. SPINK

Director, BioIncept, LLC

Dennis Spink joined the BioIncept Board of Directors in 2010 after serving as an advisor since 2006. As a 44-year veteran of Wall Street, focusing on the debt capital markets, Mr. Spink brings a broad range of financial experience and management to the Board. Prior to joining BioIncept, he served as a managing director at a number of firms including L.F. Rothschild and Wachovia Securities and was an Executive Director at Oppenheimer & Co. Mr. Spink received his BA in Biology from Adelphi University and is a published co-author in the Journal of Oncology.